Novo Nordisk shares fell sharply after it said a pill with the key ingredient in Ozempic and Wegovy didn't slow Alzheimer's disease in two late-stage clinical trials

Core Insights - Oral semaglutide, the active ingredient in the obesity and diabetes medications Ozempic and Wegovy, did not demonstrate efficacy in slowing Alzheimer's disease progression in two late-stage clinical trials [1] Group 1: Clinical Trial Results - The late-stage clinical trials for oral semaglutide showed no significant impact on the progression of Alzheimer's disease [1] - The findings indicate that the expectations for oral semaglutide as a treatment for Alzheimer's may need to be reassessed [1]